AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03290430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Counseling
Description: 8 video call sessions over 4 weeks. Lasting 30-45 minutes each
Study NCT03290430 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Texting support
Description: Texts with smoking cessation support throughout the program
Study NCT03290430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
Study NCT00841217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW501516
Description: 2.5mg/day
Study NCT00841217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Study NCT00859729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pVAXrcPSAv53l (DNA encoding rhesus PSA)
Description: 5 doses, 4 weeks apart
Study NCT00859729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMA VAX™ intradermal DNA delivery system
Description: in vivo electroporation is applied after each DNA injection
Study NCT02626988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of a biodiverse diet
Description: Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
Study NCT04200001 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: The patient will receive the following questionnaires to be completed :~* EORTC QLQ-C30~* EORTC QLQ-BR23~* EORTC SHQ-C22~* CUPIDON 2 specific questionnaire
Study NCT04999618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haemoblock
Description: Delivering with transdermal patches
Study NCT04999618 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivering with transdermal patches
Study NCT04435678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ALEX² test using the MAX 45k automated laboratory system
Description: The ALEX² test system is a quantitative in vitro diagnostic (IVD) test for the measurement of allergen specific IgE (sIgE) and a semi-quantitative in vitro diagnostic test for the measurement of total IgE (tIgE) in human serum or plasma (exception EDTA plasma).~The MAX 45k analyzer is intended for an automated in-vitro diagnostics use for quantitative determination of allergen specific Immunoglobulin E and semi-quantitative determination of total IgE. The MAX 45k is suitable for human serum or plasma (Heparin, Citrat, but no EDTA). MAX 45k is intended to be used only in conjunction with RAPTOR SERVER analysis software and ALEX based technology arrays.
Study NCT00772330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaucoma Drainage Device
Description: Insertion of MIDI Arrow subconjunctivally with a fornix-based incision after pretreatment of scleral surface with 0.4 mg/mL MMC and insertion of MIDI Arrow tube through sclera into anterior chamber of eye
Study NCT00201708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
Study NCT00201708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
Study NCT00201708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (AC)
Description: 600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
Study NCT02819427 — intervention group
Intervention type: DEVICE
Intervention: Near Infra Red Spectroscopy (NIRS)
Study NCT02819427 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) in a simultaneous High-Resolution (HR) recording.
Study NCT05602792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with advanced solid tumors.
Study NCT05602792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with sarcoma.
Study NCT05602792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with Malignant head and neck tumor.
Study NCT05602792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with breast cancer.
Study NCT05602792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with esophagus cancer.
Study NCT05602792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with lung cancer.
Study NCT05602792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through intratumoral injection in patients with non-melanoma skin cancer.
Study NCT01749111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM A Cyclophosphamide
Description: Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation
Study NCT01749111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARM B Calcineurin inhibitor and methotrexate
Description: Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
Study NCT03798782 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ross procedure
Description: The patient will undergo the Ross procedure where the surgeon will replace the aortic valve using a pulmonary autograft (Ross procedure) with pulmonary homograft replacement of the pulmonary root. Identified Ross experts will perform all Ross procedures.
Study NCT03798782 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional aortic valve replacement
Description: The patient will undergo Conventional aortic valve replacement where the surgeon will replace the aortic valve with another prosthesis which can include a mechanical prosthesis, a stented biological prosthesis, a stentless biological valve or root, or a catheter valve.
Study NCT03199118 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF +SCTG
Description: the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
Study NCT03199118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CAF +SCTG
Description: the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
Study NCT03199118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet rich fibrin
Description: in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
Study NCT04958642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrabetadex
Description: Mallinckrodt test formulation, administered intrathecal (IT) via lumbar puncture (LP) infusion.
Study NCT02182947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
Study NCT03582943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLIC
Description: See descriptions under arm/group descriptions. RLIC is delivered for 7 visits, occurring on consecutive weekdays.
Study NCT03582943 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham conditioning
Description: See descriptions under arm/group descriptions. Sham conditioning is delivered for 7 visits, occurring on consecutive weekdays.
Study NCT03582943 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
Study NCT03582943 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. This is a motor learning task. Participants perform the balance task for 15, 30-second trials per day at visits 3-7.
Study NCT00453375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHT-3021
Description: Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
Study NCT00453375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BHT-Placebo
Description: Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
Study NCT02659501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
Study NCT02659501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with epinephrine
Description: Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
Study NCT02659501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine sulfate
Description: Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
Study NCT02659501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Description: Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
Study NCT02659501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/acetaminophen
Description: Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
Study NCT02659501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/acetaminophen
Description: Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
Study NCT02659501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
Study NCT02659501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
Study NCT01055990 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
Description: The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
Study NCT01055990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood fix
Description: The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
Study NCT04805268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F FDG PET/CT
Description: 18F FDG PET/CT imaging (fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography).
Study NCT02236988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Immediate Release
Description: 30 mg immediate release tablets
Study NCT03202342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + ethyl butyrate 0 C
Description: Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
Study NCT02038153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02038153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT02343393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Study NCT02343393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate
Study NCT01101035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat tablets
Study NCT01101035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol tablets
Study NCT01867749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy (IPT-G)
Study NCT01867749 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping with Depression (CWD)
Study NCT00555880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride
Description: one dose, 10-30mg, given orally
Study NCT00555880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03584165 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BIIB111
Description: Administered as specified in the treatment arm.
Study NCT03584165 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: BIIB112
Description: Administered as specified in the treatment arm.
Study NCT05083429 — intervention group
Intervention type: DRUG
Intervention: Salmeterol
Description: Salmeterol inhaler dispensing claim is used as the reference
Study NCT05083429 — intervention group
Intervention type: DRUG
Intervention: Tiotropium
Description: Tiotropium dispensing claim is used as the reference
Study NCT04551118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) -active
Description: Transcranial alternating current stimulation (tACS) is a non-invasive neuromodulation technique of the brain with an AC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA alternating current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
Study NCT04551118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)-active
Description: Transcranial direct current stimulation (tDCS) is a non- invasive neuromodulation technique of the brain with a DC micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive 20 min sessions of 1.5 mA direct current delivered over the dorsolateral prefrontal cortex, for 7 consecutive days.
Study NCT04551118 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial electrical stimulation (TES)-sham
Description: Transcranial electrical stimulation (TES) is a non-invasive neuromodulation technique of the brain with micro-electrical stimulator, two rubber electrodes in saline-soaked sponges, and a control software to set the output of the stimulation type. Participants receive sham stimulation over the dorsolateral prefrontal cortex, with current turned off after 30 second. The session last 20 min for 7 consecutive days.
Study NCT00997919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: single SC dose
Study NCT00997919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MABT5102A
Description: single IV dose
Study NCT02430090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: this used in intratechal area and for spinal anesthesia in ceserean section
Study NCT02430090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: this used in intratechal area and for spinal anesthesia in ceserean section
Study NCT02430090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: this used in intratechal area and for spinal anesthesia in ceserean section
Study NCT02750852 — intervention group
Intervention type: PROCEDURE
Intervention: Total hip arthroplasty, blood loss analysis
Description: Data analysis about blood loss in total hip replacement
Study NCT02638324 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Renal nervous denervation
Description: The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
Study NCT04593108 — intervention group
Intervention type: DEVICE
Intervention: Letrozole misoprostol
Description: Letrozole give pretreatment of abortion by misoprostol
Study NCT04593108 — intervention group
Intervention type: DRUG
Intervention: Misoprostol, placebo
Description: Give placebo pretreatment of abortion by misoprostol
Study NCT00799266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: intravenous infusion
Study NCT00799266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion
Study NCT04491968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Oriented Recovery Enhancement
Description: MORE sessions involve mindfulness training to prevent opioid relapse and reduce pain, cognitive reappraisal to decrease negative affect and regulate opioid craving, and savoring to augment natural reward processing and evoke positive emotion. Each session begins with a mindful breathing meditation, followed by a debriefing session. The therapist then debriefs participants' homework practice of using mindfulness, reappraisal, and savoring skills to cope with pain and enhance well-being in everyday life. During this debrief of the homework. Next, new psychoeducational material is introduced. Sessions culminate with an experiential exercise, and close with a brief mindful breathing meditation. Participants are asked to practice 15 minutes of mindfulness/reappraisal/savoring skills each day.
Study NCT04491968 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Methadone Treatment as Usual
Description: In the methadone programs, clients typically come to the clinic regularly to get their methadone dose. Clients see their clinic substance abuse counselor for individual counseling, usually weekly at the beginning of treatment, with decreasing frequency if they remain abstinent and progress through treatment. Depending on clients' stage of MMT and success with remaining abstinent from drugs, they may be required to attend clinic treatment groups. Also, some clients may choose to go to voluntary counseling, educational, or support groups.
Study NCT02535325 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3-D conformal RT
Study NCT02535325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02535325 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02535325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine
Description: Given PO
Study NCT02535325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyamine Hydrochloride
Description: Given PO
Study NCT02535325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study NCT02535325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV